Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Lung03: ifinatamab deruxtecan with atezolizumab with or without carboplatin in first-line extensive-stage small cell lung cancer
2023-509629-36-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ifinatamab deruxtecan in small cell lung cancer (SCLC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 8 more. Planned start Oct 2025; status: authorised.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-509629-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509629-36-00.